

FESPIXON[®] cream

**A Game Changer
to H.E.A.L. DFU**



FESPIXON[®] H.E.A.L.


Heals DFU **E**fficaciously **A**pproved as Prescription Only Medication with unique MoA **L**essen healthcare burden



Overall, **about 61%** of patients achieve complete healing within only **16 weeks**.


Heals DFU Efficaciously

FESPIXON[®] exhibited superior and faster efficacy in the healing of DFUs.



Approved as Prescription Only Medication with unique MoA

FESPIXON[®] innovatively modulates M1/M2 macrophages, suppresses inflammation, and improves ulcer healing.




FESPIXON[®] can exert the functions of

- (1) promoting angiogenesis and increase blood flow by regulating VEGF
- (2) releasing TGF to recruit the stem cells to the lesion for tissue regeneration and promote fibroblast proliferation
- (3) synthesizing collagen via hydroxyproline and trigger extracellular matrix collagen deposition as to achieve complete healing of wounds.

Lessen healthcare burden

Apply *FESPIXON*[®]




FESPIXON[®] H.E.A.L.



Heals DFU

60.7% vs 35.1%
Superior to absorbent dressing



robust Efficacy

about 61%
of patients achieve complete healing



Approved with unique MoA

The **1st** approved macrophage-regulating for DFU treatment



Lessen healthcare burden

- **Simple application** method
- Easy use at home

The Ph3 data and the mechanism of action of Fespixon have been published on the *JAMA Network Open*.

JAMA Network | **Open**[™]

JAMA Netw Open. 2021; 4 (9):e2122607.
doi:10.1001/jamanetworkopen.2021.22607

Scan QRCode for the full text



Fespixon's clinical meaningfulness as a macrophage-regulation new drug compared with other DFU treatments has been reviewed and published in *Pharmaceutics*.



pharmaceutics

Pharmaceutics 2022, 14 (10), 2065;
https://doi.org/10.3390/pharmaceutics14102065

Scan QRCode for the full text



The findings of the MoA studies on Fespixon (ON101) have been published by *JID Innovations*.

JID INNOVATIONS
Skin Science from Molecules to Population Health

Published: June 01,
2022 DOI: https://doi.org/10.1016/j.xjidi.2022.100138

Scan QRCode for the full text



FESPIXON® clinical cases

A 53-year-old female patient with multiple DFU treatment failures.

Patients had undergone various treatments including NPWT, HBOT, etc. without success for five months achieved complete healing after 16 weeks of treatment with FESPIXON cream.



Before treatment

Ulcer presented after debridement



After 6 weeks

The wound area has significantly reduced



After 16 weeks

Wound healing



A 55-year-old female patient with poor blood sugar control

HbA1c as high as 13.2%, with a DFU wound area greater than 100 cm², Continued treatment with FESPIXON resulted in good wound healing and avoided further amputation.



Before treatment

Ulcer presented after toe amputation



After 5 weeks

Granulation tissue begins to grow



After 9 weeks

Skin grafting surgery



After 26 weeks

Wound healing



70-year-old female patient with a Wagner grade 4 Ulcers

A diabetic and hypertensive dialysis patient continued treatment with FESPIXON after amputation debridement to prevent the occurrence of further amputation.



Before treatment

Wound area: 60 cm²



After 8 weeks

Granulation tissue grows rapidly



After 34 weeks

Tissue gradually forms



After 43 weeks

Wound healing



Abbreviation

CI = confidence interval; DFU = allergic bronchopulmonary aspergillosis; HBOT = hyperbaric oxygen therapy; M1 = classical activated macrophage; M2 = alternatively activated macrophage; NPWT = negative pressure wound therapy; OR = odds ratio

Reference

1. Lin CW, et al. JID Innov. 2022 Jun 2;2(5):100138.; 2. Huang YY, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2122607.; 3. McDermott K, et al. Diabetes Care. 2023 Jan; 46(1): 209–221.; 4. Markuson M, et al. Adv Skin Wound Care. 2009 Aug;22(8):365-72.

